i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance

i-sense：EPSRC IRC 在传染病和抗菌素耐药性敏捷预警传感系统中的应用

• 批准号: EP/R00529X/1
• 负责人: Rachel McKendry
• 金额: $ 547.98万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FR00529X%2F1
• 关键词: sense; EPSRC; IRC; Agile; Early

In 2017 the need for disruptive sensing systems to detect and limit infectious outbreaks has taken centre stage - Zika virus and Ebola add to the threat of pandemic influenza, HIV and antimicrobial resistance, for which the world remains unprepared. Infections are a global problem and our response must therefore be global in nature. The House of Commons Ebola report recognised the 'heroic' work of scientists, researchers and agencies but highlighted that 'the UK response - like the international response - was undermined by systemic delay' and 'we must take the opportunity now to ensure that the UK is not caught unprepared when the next disease emergency strikes. Lives can be lost for every day of delay.' The i-sense2 EPSRC IRC aims to engineer a new generation of agile and globally impactful early warning sensing systems for infectious diseases and antimicrobial resistance. We are harnessing the power of mobile phones, biomedical engineering, nanotechnology, genomics and big data to detect outbreaks much earlier than ever before. Next Steps funding is pivotal to; maximising the impact of our current IRC research programme, retaining key staff and delivering a step change in our capabilities to respond to emerging infections and antimicrobial resistance. This will in-turn leverage over £10M in translational 'test bed' infrastructure, new laboratories, academic positions, studentships and industry partnerships to help ensure our sustainability as a National Centre of Excellence. We will build on our pioneering work within our current i-sense IRC which focused on three infectious diseases - influenza, HIV and C. difficile. The step change we now propose is to engineer more 'agile' systems that are rapidly adaptable to different diseases, antimicrobial resistant strains and different countries. Recognising the need to develop new systems through an understanding of context, i-sense2 brings together multiple disciplines, Public Health England, the Africa Health Research Institute, the Royal College of General Practitioners Research Surveillance Centre, the NIHR UCLH Biomedical Research Centre, and industry to: 1. Harness deep learning of millions of symptoms reported online (e.g. social media, searches) to track outbreaks, potentially before people visit their doctors and in resource-limited settings; 2. Build smartphone connected diagnostic tests to support front-line health-workers and self-testing. We will develop low-cost biobarcode paper microfluidic tests and handheld sequencing technologies to detect the earliest biomarkers of infection and drug-resistance, and securely send results to online infectious disease clinics;3. Create state-of-the-art visualisation tools to link patients to treatment and map disease 'hot spots' by fusing mHealth, genomic, clinical and epidemiological data; 4. Invest in the careers of our talented researchers to become future leaders;5. Grow a National Centre of Excellence supported by a plurality of funding. Our disease focus will expand to influenza-like-illnesses, sexually transmitted infections and resistant-bacteria, as exemplars of acute, chronic and emerging infections. We will build population-level 'test beds' in the UK and South Africa, to pilot our technologies and then bid for next stage translational funding for clinical trials and product development. Future 'IRC Next Steps Plus Awards' will explore new research directions e.g. sensing systems for Ebola and Zika virus.i-sense2 has the potential to bring major human and economic benefits to millions of people worldwide. Patients will benefit from receiving faster access to potentially life-saving treatment. Populations will benefit from reduced disease transmission, health systems will benefit from rapid diagnostics, and patient self-management. Industry will benefit from skilled people and new commercial opportunities. Public health will benefit from more timely interventions and pandemic preparedness.

2017年，检测和限制传染病暴发的破坏性传感系统的需求已成为焦点——寨卡病毒和埃博拉病毒加剧了大流行性流感、艾滋病毒和抗微生物药物耐药性的威胁，而世界仍未做好准备。感染是一个全球性问题，因此我们的应对措施必须是全球性的。下议院的埃博拉报告承认了科学家、研究人员和机构的“英勇”工作，但强调“英国的反应——就像国际反应一样——被系统性的拖延所破坏”，“我们现在必须抓住机会，确保英国在下一次疾病紧急情况来袭时不会措手不及。”每耽误一天，就有可能失去生命。”i-sense2 EPSRC IRC旨在设计新一代敏捷且具有全球影响力的传染病和抗菌素耐药性预警传感系统。我们正在利用移动电话、生物医学工程、纳米技术、基因组学和大数据的力量，比以往任何时候都更早地发现疫情。筹资对以下方面至关重要：最大限度地发挥我们目前的IRC研究计划的影响，留住关键人员，并在应对新出现的感染和抗微生物药物耐药性的能力方面实现阶段性变化。这将反过来利用超过1000万英镑的转化“试验台”基础设施，新实验室，学术职位，学生和行业合作伙伴关系，以帮助确保我们作为国家卓越中心的可持续性。我们将在目前的i-sense IRC内开展开创性工作，重点关注三种传染病——流感、艾滋病毒和艰难梭菌。我们现在提出的步骤变化是设计更“敏捷”的系统，使其能够迅速适应不同的疾病、抗微生物菌株和不同的国家。i-sense2认识到需要通过对背景的理解来开发新系统，它将多个学科、英国公共卫生部、非洲卫生研究所、皇家全科医生学院研究监测中心、英国国立卫生研究院UCLH生物医学研究中心和工业界联合起来：利用对在线（例如社交媒体、搜索）报告的数百万种症状的深度学习来跟踪疫情，可能在人们去看医生之前和在资源有限的环境中进行跟踪；2. 建立智能手机连接的诊断测试，以支持一线卫生工作者和自我检测。2 .开发低成本的生物条形码纸质微流控检测和手持式测序技术，检测感染和耐药的最早生物标志物，并将结果安全地发送到在线传染病诊所；创建最先进的可视化工具，通过融合移动健康、基因组、临床和流行病学数据，将患者与治疗联系起来，并绘制疾病“热点”地图；4. 4 .投资于有才华的研究人员的职业生涯，使他们成为未来的领导者；发展一个由多个基金支持的国家卓越中心。我们的疾病重点将扩大到流感样疾病、性传播感染和耐药细菌，作为急性、慢性和新发感染的范例。我们将在英国和南非建立人口水平的“试验台”，试验我们的技术，然后竞标下一阶段的临床试验和产品开发的转化资金。未来的“IRC下一步奖励”将探索新的研究方向，例如埃博拉病毒和寨卡病毒的传感系统。I-sense2有可能为全世界数百万人带来重大的人类和经济利益。患者将受益于更快获得可能挽救生命的治疗。人群将受益于疾病传播的减少，卫生系统将受益于快速诊断和患者自我管理。工业将受益于技术人员和新的商业机会。公共卫生将受益于更及时的干预措施和大流行病防范。

项目成果

OC12.06: Using online search activity for earlier detection of gynecological malignancy*

OC12.06：利用在线搜索活动及早发现妇科恶性肿瘤*

• DOI: 10.1002/uog.26400
• 发表时间: 2023
• 期刊: Ultrasound in Obstetrics & Gynecology
• 影响因子: 7.1
• 作者: Barcroft J

Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay.

• DOI: 10.1093/cid/ciac629
• 发表时间: 2023-02-18
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Coupling Lipid Nanoparticle Structure and Automated Single-Particle Composition Analysis to Design Phospholipase-Responsive Nanocarriers.

• DOI: 10.1002/adma.202200839
• 发表时间: 2022-07
• 期刊: Advanced materials (Deerfield Beach, Fla.)
• 作者: Barriga HMG;Pence IJ;Holme MN;Doutch JJ;Penders J;Nele V;Thomas MR;Carroni M;Stevens MM
• 通讯作者: Stevens MM

A decade in review: use of data analytics within the biopharmaceutical sector.

• DOI: 10.1016/j.coche.2021.100758
• 发表时间: 2021-12
• 期刊: Current opinion in chemical engineering
• 影响因子: 6.6
• 作者: Banner M;Alosert H;Spencer C;Cheeks M;Farid SS;Thomas M;Goldrick S
• 通讯作者: Goldrick S

Deprivation and exposure to public activities during the COVID-19 pandemic in England and Wales.

• DOI: 10.1136/jech-2021-217076
• 发表时间: 2022-04
• 期刊: Journal of epidemiology and community health
• 影响因子: 6.3
• 作者: Beale S;Braithwaite I;Navaratnam AM;Hardelid P;Rodger A;Aryee A;Byrne TE;Fong EWL;Fragaszy E;Geismar C;Kovar J;Nguyen V;Patel P;Shrotri M;Aldridge R;Hayward A;Virus Watch Collaborative
• 通讯作者: Virus Watch Collaborative